209 related articles for article (PubMed ID: 31863326)
1. The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies.
Verrips A; Dotti MT; Mignarri A; Stelten BML; Verma S; Federico A
Neurol Sci; 2020 Apr; 41(4):943-949. PubMed ID: 31863326
[TBL] [Abstract][Full Text] [Related]
2. Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.
Amador MDM; Masingue M; Debs R; Lamari F; Perlbarg V; Roze E; Degos B; Mochel F
J Inherit Metab Dis; 2018 Sep; 41(5):799-807. PubMed ID: 29560583
[TBL] [Abstract][Full Text] [Related]
3. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults.
Mandia D; Chaussenot A; Besson G; Lamari F; Castelnovo G; Curot J; Duval F; Giral P; Lecerf JM; Roland D; Pierdet H; Douillard C; Nadjar Y
J Neurol; 2019 Aug; 266(8):2043-2050. PubMed ID: 31115677
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.
Huidekoper HH; Vaz FM; Verrips A; Bosch AM
Eur J Pediatr; 2016 Jan; 175(1):143-6. PubMed ID: 26156051
[TBL] [Abstract][Full Text] [Related]
5. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment.
Martini G; Mignarri A; Ruvio M; Valenti R; Franci B; Del Puppo M; Federico A; Nuti R; Dotti MT
Calcif Tissue Int; 2013 Mar; 92(3):282-6. PubMed ID: 23212544
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.
Mignarri A; Magni A; Del Puppo M; Gallus GN; Björkhem I; Federico A; Dotti MT
J Inherit Metab Dis; 2016 Jan; 39(1):75-83. PubMed ID: 26153518
[TBL] [Abstract][Full Text] [Related]
7. Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.
Catarino CB; Vollmar C; Küpper C; Seelos K; Gallenmüller C; Bartkiewicz J; Biskup S; Hörtnagel K; Klopstock T
J Neurol; 2018 Feb; 265(2):388-393. PubMed ID: 29260356
[TBL] [Abstract][Full Text] [Related]
8. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.
Verrips A; Wevers RA; Van Engelen BG; Keyser A; Wolthers BG; Barkhof F; Stalenhoef A; De Graaf R; Janssen-Zijlstra F; Van Spreeken A; Gabreëls FJ
Metabolism; 1999 Feb; 48(2):233-8. PubMed ID: 10024088
[TBL] [Abstract][Full Text] [Related]
9. Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study.
Mondelli M; Sicurelli F; Scarpini C; Dotti MT; Federico A
J Neurol Sci; 2001 Sep; 190(1-2):29-33. PubMed ID: 11574103
[TBL] [Abstract][Full Text] [Related]
10. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
Dotti MT; Lütjohann D; von Bergmann K; Federico A
Neurol Sci; 2004 Oct; 25(4):185-91. PubMed ID: 15549503
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis.
Ito S; Kuwabara S; Sakakibara R; Oki T; Arai H; Oda S; Hattori T
J Neurol Sci; 2003 Dec; 216(1):179-82. PubMed ID: 14607320
[TBL] [Abstract][Full Text] [Related]
12. Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis.
Stelten BML; Bonnot O; Huidekoper HH; van Spronsen FJ; van Hasselt PM; Kluijtmans LAJ; Wevers RA; Verrips A
J Inherit Metab Dis; 2018 Jul; 41(4):641-646. PubMed ID: 28894950
[TBL] [Abstract][Full Text] [Related]
13. Early diagnosed cerebrotendinous xanthomatosis patients: clinical, neuroradiological characteristics and therapy results of a single center from Turkey.
Zubarioglu T; Kiykim E; Yesil G; Demircioglu D; Cansever MS; Yalcinkaya C; Aktuglu-Zeybek C
Acta Neurol Belg; 2019 Sep; 119(3):343-350. PubMed ID: 29058268
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
Salen G; Steiner RD
J Inherit Metab Dis; 2017 Nov; 40(6):771-781. PubMed ID: 28980151
[TBL] [Abstract][Full Text] [Related]
15. Treatment and follow-up of children with cerebrotendinous xanthomatosis.
van Heijst AF; Verrips A; Wevers RA; Cruysberg JR; Renier WO; Tolboom JJ
Eur J Pediatr; 1998 Apr; 157(4):313-6. PubMed ID: 9578968
[TBL] [Abstract][Full Text] [Related]
16. Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
Weissfeld T; Ratliff J
J Clin Neurosci; 2018 Jul; 53():263-264. PubMed ID: 29731275
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
[TBL] [Abstract][Full Text] [Related]
18. Enhanced susceptibility of LDL to oxidative modification in a CTX patient:- role of chenodeoxycholic acid in xanthoma formation.
Kinoshita M; Kawamura M; Fujita M; Hirota D; Suda T; Taki M; Kusano J; Takao K; Takenaka H; Kubota S; Teramoto T
J Atheroscler Thromb; 2004; 11(3):167-72. PubMed ID: 15256768
[TBL] [Abstract][Full Text] [Related]
19. Patients with Lately Diagnosed Cerebrotendinous Xanthomatosis.
Yunisova G; Tufekcioglu Z; Dogu O; Bilgic B; Kaleagasi H; Akca Kalem S; Lohmann E; Gurvit HI; Emre M; Hanagasi HA
Neurodegener Dis; 2019; 19(5-6):218-224. PubMed ID: 32349000
[TBL] [Abstract][Full Text] [Related]
20. Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment.
Alhariri A; Hamilton K; Oza V; Cordoro K; Sobreira NL; Malloy M; Slavotinek A
Am J Med Genet A; 2017 Aug; 173(8):2275-2279. PubMed ID: 28590052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
